Bio Protocol launches Aubrai, the first-ever decentralized AI agent for longevity science
Bio Protocol has introduced Aubrai, the world’s first decentralized BioAgent designed to accelerate longevity research.
- Co-developed with VitaDAO and informed by Dr. Aubrey de Grey’s longevity research, Aubrai leverages decentralized mechanisms to overcome traditional funding gaps and accelerate translational science.
- Aubrai can generate and validate research hypotheses, design wet-lab experiments, and securely encrypt data.
Bio Protocol ( BIO ) has launched Aubrai, the world’s first decentralized AI agent designed to advance longevity research.
The launch price is set at 0.585 BIO per AUBRAI.
The ongoing sale, conducted on the BASE blockchain, set a fundraising target of 234,000 BIO and has already been oversubscribed 13.5x.
Source: bio.xyz
About Bioprotocol’s Aubrai
Co-developed by Bio Protocol and VitaDAO, Aubrai is the world’s first decentralized BioAgent, drawing knowledge from thousands of private lab notes, internal chats, and unpublished insights from the lab of Dr. Aubrey de Grey. De Grey is best known for pioneering longevity research through his Strategies for Engineered Negligible Senescence (SENS) framework and advocating the idea that aging is a disease that can be treated.
“The consequences of traditional financing are a chronic funding gap, over-reliance on philanthropy, and a ‘valley of death’ between discovery and the clinic. That’s why we champion alternative mechanisms – DAOs, longevity-focused venture funds, and DeSci platforms – which can tolerate long horizons, align incentives around societal benefit, and crowd-source risk,” de Grey told CoinDesk in an interview.
Aubrai functions as an on-chain AI co-scientist. It can generate and validate hypotheses, design wet-lab experiments, and encrypt data to protect trade secrets while enriching research outputs. At the heart of Aubrai’s mission is the Robust Mouse Rejuvenation (RMR2) project — de Grey’s ambitious study aiming to double the remaining lifespan of middle-aged mice. Aubrai has already demonstrated its capabilities in the RMR2 study, suggesting methodological tweaks and flagging dosing caveats.
AUBRAI token holders gain governance rights over the agent’s research outputs. They also share in potential revenues from discoveries commercialized by the project.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Chainlink's Strategic Breakout Potential: Is $31 the Gateway to a Multi-Stage Bull Run?
- Chainlink (LINK) faces critical $31 resistance in late 2025, with technical patterns suggesting potential breakout to $47–$219. - Institutional adoption surges via U.S. Commerce Department partnership, whale activity, and $2.8M token buybacks boosting liquidity. - Historical backtesting warns 30-day resistance tests often trigger 6.5% average declines, highlighting mean reversion risks. - Symmetrical triangle pattern and Elliott Wave III imply $52–$98 targets if $31 is breached, but $21–$22 retracement o
Ethereum's Institutional Momentum: Analyzing Whale Activity and Market Dynamics
- A Bitcoin whale swapped $217M BTC to ETH via Hyperliquid, signaling growing institutional preference for Ethereum over Bitcoin. - Ethereum’s price rose above $4,000 as institutions poured $4B into spot ETFs and staking yields (3.8% APY) post-2025 CLARITY Act. - Ethereum’s futures open interest hit $10B, contrasting Bitcoin’s stagnant $15.3B OI, as regulators reclassified ETH as a utility token. - Whale activity and on-chain metrics (MVRV 2.15) reinforce Ethereum’s role as the crypto economy’s backbone am
Blockchain Pioneers Redefine Drug Traceability with NFT-Driven Healthcare Pact
- NVC Health partners with QuantumCTek and North China PharmaTech to integrate blockchain in healthcare via a digital asset framework agreement. - The collaboration aims to enhance drug traceability, data security, and patient record management using NFTs and quantum computing solutions. - The initiative aligns with China's national digital transformation strategy, promoting transparency and regulatory compliance in pharmaceutical supply chains. - Industry observers highlight the partnership as a proactive
Reeves: DeFi’s Openness Will Outlast Regulatory Walls
- Fold CEO Will Reeves asserts DeFi will outlast regulatory attempts to impose biometric checks and TradFi compliance measures. - He warns such controls risk undermining DeFi's open, permissionless nature and could backfire like past internet regulation failures. - Reeves highlights growing pressure from legacy institutions to favor centralized systems over decentralized platforms through policies like ETFs. - Critics argue KYC/AML mandates would erode DeFi's privacy and censorship resistance, making it in
Trending news
MoreCrypto prices
More
